Dr Macleod is a Clinical Pharmacologist with a personal chair (Teaching and Research) at the University of Aberdeen and honorary Consultant Physician within NHS Grampian. Her clinical work is largely in the area of acute stroke management, hypertension clinics and primary and secondary cardiovascular prevention. Current research interests include:
Novel imaging markers in stroke and small vessel disease using fast field cycling MRI
Using linked datasets to explore management of stroke including service organisation and secondary prevention
Interactions between stroke and other diseases (e.g. cancer)
Chair of Scotland A and B Research Ethics Committees
Honorary Deputy Secretary, British and Irish Association of Stroke Physicians
Trustee SHARP (Scottish Heart and Arterial Disease Prevention)
Latest Publications
Association of neighbourhood deprivation with secondary prevention prescribing and all-cause mortality among stroke patients in Scotland: a population-based study
Sterling, K., Turner, M., Langhorne, P., Macleod, M.
Cerebrovascular Diseases
Contributions to Journals: Articles
Impact of Rurality and Geographical Accessibility on Stroke Care and Outcomes
Statement on long-term cardiovascular consequences of maternal hypertension: Call for urgent action
Casey, H., Delles, C., Wilkinson, I. B., Banerjee, A., Andrews, M., Dawkes, S., Gatenby, K., Green, M., Head, C., Jenner, B., Lees, C., Lewis, P., MacLeod, M. J., McEniery, C., Mustafa, A., Working Group on Postpartum Care of Maternal Hypertension
Tenecteplase versus alteplase for acute stroke within 4·5 h of onset (ATTEST-2): a randomised, parallel group, open-label trial
Muir, K. W., Ford, G. A., Ford, I., Wardlaw, J. M., McConnachie, A., Greenlaw, N., Mair, G., Sprigg, N., Price, C. I., MacLeod, M. J., Dima, S., Venter, M., Zhang, L., O’Brien, E., Sanyal, R., Reid, J., Sztriha, L. K., Haider, S., Whiteley, W. N., Kennedy, J., Perry, R., Lakshmanan, S., Chakrabarti, A., Hassan, A., Marigold, R., Raghunathan, S., Sims, D., Bhandari, M., Wiggam, I., Rashed, K., Douglass, C., ATTEST-2 Investigators
The Lancet neurology, vol. 23, no. 11, pp. 1087-1096
Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial
Callahan, A., Amarenco, P., Goldstein, L. B., Sillesen, H., Messig, M., Samsa, G. P., Altafullah, I., Ledbetter, L. Y., MacLeod, M. J., Scott, R., Hennerici, M., Zivin, J. A., Welch, K. M. A., SPARCL Investigators
Archives of Neurology, vol. 68, no. 10, pp. 1245-1251
Statin treatment and stroke outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial
Goldstein, L. B., Amarenco, P., Zivin, J., Messig, M., Altafullah, I., Callahan, A., Hennerici, M., MacLeod, M. J., Sillesen, H., Zweiffler, R., Michael, K., Welch, A., SPARCL Investigators
Sequence variants on chromosome 9p21.3 confer risk for atherosclerotic stroke
Gschwendtner, A., Bevan, S., Cole, J. W., Plourde, A., Matarin, M., Ross-Adams, H., Meitinger, T., Wichmann, E., Mitchell, B. D., Furie, K., Slowik, A., Rich, S. S., Syme, P. D., MacLeod, M. J., Meschia, J. F., Rosand, J., Kittner, S. J., Markus, H. S., Mueller-Myhsok, B., Dichgans, M., Int Stroke Genetics Consortium
